After spending 20 years at Novartis, Radiopharm Theranostics Ltd. CEO Riccardo Canevari told BioWorld that when he joined Radiopharm he wanted to focus on something different within radiopharmaceuticals where no one was playing. “I believe these new modalities are at the beginning of their potential, much like in the immuno-oncology space years ago. That’s a nice place to be,” he said, but it’s not only about competition, it’s also about understanding what other companies are doing and if there is a disease area or a mechanism of action that is not being explored, he said.
In what was more of a campaign speech accompanied by frequent chants of “four more years,” U.S. President Joe Biden loaded the annual State of the Union address March 7 with what sounded like campaign promises for a second term. Among those promises were calls to Congress to expand the prescription drug price provisions of the 2022 Inflation Reduction Act.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Creative Medical Technology, Fresenius Kabi, Ionctura, Mind Medicine.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3T, Ambrx, Astellas, Citius, J&J, Kronos, Merck.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alligator, Alphyn, Arch, Gabather, Gilead, GSK, Immuron, Nodthera, Persica, Salix, Ultimovacs, Upstream, Viiv.
RSS
